Kanvas Biosciences is taking a major step forward in microbiome therapeutics with the announcement of $48 million in Series A funding, which will support a clinical trial later this year for the company’s lead cancer immunotherapy treatment.
Kanvas Biosciences is taking a major step forward in microbiome therapeutics with the announcement of $48 million in Series A funding, which will support a clinical trial later this year for the company’s lead cancer immunotherapy treatment.